UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Journal of clinical oncology, 2017-12, Vol.35 (35), p.3898-3905

2017

Volltextzugriff (PDF)

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Leukemia, 2020-08, Vol.34 (8), p.2184-2197

2020

Volltextzugriff (PDF)

Cerebral amyloid-β PET with florbetaben (18 F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

Lancet neurology, 2011-05, Vol.10 (5), p.424-435

2011

Volltextzugriff (PDF)

VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study

British journal of ophthalmology, 2013-03, Vol.97 (3), p.278-284

2013

Volltextzugriff (PDF)

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

CPT: pharmacometrics and systems pharmacology, 2023-11, Vol.12 (11), p.1666-1686

2023

Volltextzugriff (PDF)

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion

Ophthalmology (Rochester, Minn.), 2014, Vol.121 (1), p.202-208

2014

Volltextzugriff (PDF)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

Annals of oncology, 2017-09, Vol.28 (9), p.2169-2178

2017

Volltextzugriff (PDF)

Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen

Clinical pharmacology and therapeutics, 2024-05, Vol.115 (5), p.1092-1104

2024

Volltextzugriff (PDF)

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

American journal of hematology, 2020-04, Vol.95 (4), p.362-371

2020

Volltextzugriff (PDF)

PI3K inhibitors in haematological malignancies

The lancet oncology, 2022-08, Vol.23 (8), p.e365-e365

2022

Volltextzugriff (PDF)

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study

Ophthalmology (Rochester, Minn.), 2014-01, Vol.121 (1), p.202-208

2014

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.3629-3631

2022

Volltextzugriff (PDF)

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Blood, 2022-11, Vol.140 (Supplement 1), p.6470-6473

2022

Volltextzugriff (PDF)

Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7555-7555

2023

Volltextzugriff (PDF)

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Blood, 2021-11, Vol.138 (Supplement 1), p.3538-3538

2021

Volltextzugriff (PDF)

Abstract CT084: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL): CHRONOS-2

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT084-CT084

2016

Volltextzugriff (PDF)

Abstract CT084: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alphadelta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL): CHRONOS-2

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT084-CT084

2016

Volltextzugriff (PDF)

Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT001-CT001

2021

Volltextzugriff (PDF)

Patient-reported outcomes from a phase 2 study of copanlisib in patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e18123-e18123

2017

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.1531-1531

2019

Volltextzugriff (PDF)

Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6602-6602

2019

Volltextzugriff (PDF)

Abstract CT212: CHRONOS-2: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT212-CT212

2015

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up

The aging male, 2012-12, Vol.15 (4), p.198-207

2012

Volltextzugriff (PDF)

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Blood advances, 2021-02, Vol.5 (3), p.823-828

2021

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Cerebral amyloid-β PET with florbetaben (18 F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

PI3K inhibitors in haematological malignancies

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Abstract CT084: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL): CHRONOS-2

Abstract CT084: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alphadelta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL): CHRONOS-2

Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

Patient-reported outcomes from a phase 2 study of copanlisib in patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib

Abstract CT212: CHRONOS-2: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL)

A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Suchergebnisse filtern